Axol Bioscience Ltd.

Name: Axol Bioscience Ltd.
Address: Cambridge, CB101XL, GB
Telephone: +44(0)1223 751 051

Home
United Kingdom
Cambridge
Axol Bioscience Ltd.

The Best Human Cell Culture Systems for Research Success Contact Axol Bioscience today! www.axolbio.com

Axol offer ready-made, well-characterized stem and functional cells complete with easy-to-understand protocols and video guides for handling them. We are devoted to making high quality, data-rich cellular products that are affordable for all research labs including starting up labs! We believe that all research labs should have easy access to the cells generated using the reprogramming and downstream differentiation technologies.

04/09/2026

We'll be at the HEAT-Net 26: Frontiers in Research on Neurodegenerative Disorders on 10-11 September in Edinburgh

Our Head of Scientific Programs, Sapna Vyas, and Manufacturing Site Lead, Ana Marin Navarro, will be attending and look forward to connecting with researchers advancing our understanding of neurodegenerative disease.

Organised by the UK Dementia Research Institute, this year's meeting marks the 5th HEAT-Net conference and the first time it will be hosted in the UK. The programme brings together leading researchers working across Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and ALS, with sessions covering genetics, disease mechanisms, biomarkers, and therapeutics, alongside opportunities for scientific discussion during poster sessions.

If you're attending, stop by and say hello to the team. If not, explore our neuroscience portfolio and discover the human iPSC-derived models supporting neurodegeneration research: https://hubs.la/Q04vRJx50

02/09/2026

Synaptic dysfunction is increasingly recognized as an early feature of ALS. Using patient-derived iPSC neurons, Shum and colleagues showed that ALS-associated FUS mutations increase synapse formation and synaptic activity while reducing FMRP expression. The study provides new insight into how FUS mutations may contribute to neuronal dysfunction and neurodegeneration in ALS.

Key findings

• Increased pre- and postsynaptic protein expression promoted synaptogenesis and synaptic activity

• Mutant FUS neurons showed greater vulnerability to glutamate excitotoxicity

• Reduced FMRP levels suggest altered regulation of synaptic protein expression

• The study identifies a potential mechanistic link between ALS and Fragile X-related pathways

• Patient-derived iPSC models revealed early synaptic changes that may contribute to neurodegeneration

These findings further support the idea that synaptic dysfunction is an early event in ALS and highlight the value of human iPSC-derived neuronal models for uncovering disease mechanisms and identifying novel therapeutic targets.

Read the full paper: https://hubs.la/Q04vRTW70

At Axol Bioscience, we support ALS research with human iPSC-derived motor neurons, astrocytes, microglia, and co-culture systems support to model neurodegeneration and neuron-glia interactions.

Learn more about our PRISM initiative and explore our portfolio of familial and sporadic ALS patient-derived iPSC models: https://hubs.la/Q04vRNtD0

Contact us at [email protected]

26/08/2026

Adenine base editing for retinal dystrophy treatment

In this study, the authors evaluated adenine base editing (ABE) as a potential gene correction strategy for inherited retinal dystrophies (IRDs), focusing on the AIPL1 c.665G>A (p.Trp222)* mutation that causes Leber congenital amaurosis type 4 (LCA4). Researchers screened several IRD-associated mutations in patient-derived induced pluripotent stem cells (iPSCs) and found that the AIPL1 mutation was the most suitable target, achieving efficient and precise correction with limited bystander editing.

The corrected cells were used to generate retinal organoids, enabling assessment in a disease-relevant human retinal model. ABE components were delivered either by chemically modified mRNA/sgRNA lipofection or by a dual-AAV split-intein system. Both approaches restored expression of the missing AIPL1 protein in subsets of photoreceptor cells and rescued downstream phototransduction proteins PDE6α and PDE6β, indicating functional recovery. Some reduction in pathological cGMP accumulation was also observed.

The authors conclude that ABE shows strong promise for treating specific IRD mutations and that retinal organoids provide an effective platform for preclinical evaluation. However, improvements in editing efficiency, delivery methods, and minimization of off-target effects are still required before clinical translation.

Read the full paper: Adenine base editor correction of pathogenic variations associated with inherited retinal dystrophy in patient iPSC and retinal organoids: https://hubs.la/Q04vlrGZ0

Our human retinal organoid models provide a physiologically relevant platform for studying disease biology, enabling deeper insights into pathological mechanisms and their progression. Learn more: https://hubs.la/Q04vlrnf0

21/08/2026

Retinal toxicity assessment using human iPSC-derived retinal organoids

In our latest blog, we explore how human iPSC-derived retinal organoids provide access to human retinal biology within a controlled, physiologically relevant in vitro system. By recapitulating key features of retinal development and the cellular complexity of the human retina, these models support the generation of more predictive safety data during drug discovery and preclinical development.

Key takeaways

• Retinal organoids recapitulate key features of retinal development and contain the major cell types found in the neural retina

• Multiple complementary assays, including viability, morphology, apoptosis and gene expression analyses, can be combined to generate a comprehensive toxicity profile

• Retinal organoids respond reproducibly to compounds with established retinal toxicity profiles, supporting their use in preclinical safety evaluation

Read the full blog: https://hubs.la/Q04tQsFQ0

19/08/2026

Loss of INPP5E affects photoreceptor outer segment membrane biogenesis in iPSC-derived human retinal organoids

In this study, Whiting et al., investigated the role of INPP5E, a ciliary phosphatase implicated in Joubert syndrome and retinitis pigmentosa, using human induced pluripotent stem cell-derived retinal organoids carrying an INPP5E D477N/D477N loss-of-function mutation.

The mutant organoids developed normally overall but showed a transient delay in early photoreceptor precursor differentiation, evidenced by reduced expression of photoreceptor markers at early stages. In mature organoids, loss of INPP5E disrupted photoreceptor ciliary function and outer segment organization.

Key findings included mislocalization of the ciliary protein ARL13B and the visual pigment rhodopsin, increased numbers of rod and cone photoreceptors, and significantly elongated photoreceptor outer segments. The mutation also altered actin and microtubule organization, suggesting defects in cytoskeletal regulation and membrane biogenesis.

The authors conclude that INPP5E is essential for proper photoreceptor structure, protein trafficking, and outer segment membrane maintenance in the human retina. The work highlights retinal organoids as a valuable model for studying human retinal ciliopathies.

Read the full paper: https://hubs.ly/Q04twnyP0

Our human retinal organoid models provide a physiologically relevant platform for studying disease biology, enabling deeper insights into pathological mechanisms and their progression. Learn more: https://hubs.ly/Q04twmyn0

12/08/2026

Microglia are increasingly recognized as key drivers of Alzheimer's disease, yet recreating long-lived, homeostatic microglia within complex human brain models remains a major challenge. Using a fully human iPSC-derived 3D Brain Tissue Model (3BTM), the Klimmt and colleagues maintained mature microglia for over six months and recapitulated key Alzheimer's disease-associated phenotypes, including amyloid pathology, tau dysregulation, and disease-associated microglial states.

Key findings

• Microglia survived for more than 6 months and maintained a ramified, homeostatic phenotype

• Multi-omics analysis showed progressive cellular maturation and brain-like characteristics

• APP mutations drove amyloid accumulation, increased phospho-tau, and induced Alzheimer's disease-associated microglial states

• Microglia actively surveilled their environment and responded rapidly to injury

• Aducanumab reduced plaque-like pathology and enhanced microglial Aβ phagocytosis

• Disease-associated glial signatures were partially reversed following treatment

These findings highlight the importance of incorporating mature human microglia into advanced multicellular brain models to study Alzheimer's disease mechanisms, neuroinflammation, and therapeutic responses.

Read the full paper : https://hubs.la/Q04syzLP0

At Axol Bioscience, we support advanced neuroinflammation and Alzheimer's disease research with human iPSC-derived microglia, neurons, astrocytes, and triculture models. Through our custom differentiation services, we can also generate APOE-derived microglia and astrocytes to help researchers model patient-specific disease biology.

Learn more about our control microglia (ax0664): https://hubs.la/Q04sy-220

Contact us at [email protected]

07/08/2026

We'll be at the ISER XXVII Biennial Meeting, 23-27 August, Valencia, Spain

Our Head of Ophthalmology, Florian Regent, and Scientific Account Manager, Yanis Kasioulis, will be on site and are looking forward to connecting with leaders from across the ophthalmology and vision research community.

The ISER Biennial Meeting brings together leading experts to discuss the latest advances in vision science, from fundamental laboratory research to clinical translation.

Florian will be giving a presentation titled "Modeling human retinal disorders with induced pluripotent stem cells" on Thursday, 27 August, 15:30-17:30, in the session "Frontiers in Genetic Medicine: Delivery, Editing, and Translational Insights".

Come and speak with our team to learn more about our human iPSC‑derived retinal cell models and organoids, as well as our specialist services designed to support and accelerate ocular research and drug development programs.

Learn more about our ophthalmology offerings: https://hubs.la/Q04scLb70

If you’re not attending ISER but would like to discuss how we can support your projects, please contact us at [email protected].

05/08/2026

Using human neuronal-glial tri-culture and microglia-containing brain organoids, the authors demonstrated that activation of the mitochondrial unfolded protein response (UPRmt) in microglia disrupts communication with neighboring neurons and astrocytes, promotes inflammatory signaling, impairs proteostasis, and drives a senescence-like phenotype.

Key findings:

• Mitochondrial stress rewires microglial metabolism and lipid homeostasis
• Stressed microglia adopt a senescence-like phenotype
• Microglial dysfunction drives inflammatory signaling and alters neuron-glia communication
• Human tri-culture and organoid models captured disease-relevant cellular interactions

These findings highlight the importance of studying neurodegeneration in complex human-relevant systems that incorporate neurons, astrocytes, and microglia.

Read the full paper: https://hubs.la/Q04rPpVc0

At Axol Bioscience, we support these studies with human iPSC-derived microglia, neurons, astrocytes, triculture models, as well as patient-derived Alzheimer's disease models, including our APOE panel and secondary tauopathy lines.

Learn more about our sporadic Alzheimer's disease APOE portfolio: https://hubs.la/Q04rPjHc0

Contact us at [email protected]

04/08/2026

Our people, our values: the foundation of success at Axol Bioscience

The work we do is only possible because of the talented people across our business who bring expertise and passion to their roles every day.

As we continue our commitment to democratise access to physiologically relevant human models of disease, our culture remains one of our greatest strengths. Built on performance, transparency, diversity & inclusivity, accountability, integrity, and collaboration, these values guide how we work, make decisions, and support one another.

We're proud that our recent employee engagement survey resulted in an Employee Net Promoter Score (eNPS) of 73, reflecting a team that feels connected to our mission and proud of the impact we're making together.

Read more about the people and values that are the foundation of success at Axol Bioscience: https://hubs.la/Q04rNfNc0

03/08/2026

Thank you for joining our recent webinar with Optics11 Life and King's College London. We hope you found the session valuable and enjoyed the discussion on combining advanced electrophysiology with physiologically relevant in vitro models.

If you’d like to explore this area further, we invite you to learn more about our cardiovascular offerings: https://hubs.la/Q04rCVZ50

Cardiac safety and disease‑relevant models

Extensively characterised iPSC‑derived ventricular and atrial cardiomyocyte models capture key cardiac functional endpoints with consistent readouts, including action potential dynamics, conduction velocity, contractility, and chamber‑specific pharmacology. Ventricular cardiomyocytes are CiPA‑validated models supporting consistent assessment of pro‑arrhythmic risk and regulatory‑relevant cardiac safety profiling. These systems support NAMs (New Approach Methodologies) for more predictive, physiologically relevant testing.

Cardiac model optimisation and maturation

For applications requiring enhanced maturity, we provide MyoMax™ cardiac maturation media, which improves functional and structural characteristics of human iPSC‑derived ventricular cardiomyocytes, including reduced spontaneous beat rate, improved conduction velocity, shortened action potential duration, increased expression of maturity‑associated cardiac genes, and improved sarcomere alignment and expression of cardiac maturity markers.

In vitro cardiovascular model & assay development with platform integration

Services include complex model development of advanced cardiac models, custom protocol design and optimization, model characterization, phenotypic analysis, treatment titration and endpoint assays, integration with MPS and other platforms and collaborative scale-up for transfer to higher throughput platforms and CRO, or in-house workflows.

Cardiotoxicology and candidate drug testing in human iPSC‑derived models

Candidate drug testing and cardiac safety assessment using human iPSC‑derived cardiomyocyte models. Services and capabilities include evaluation of drug effects on cardiac electrophysiology, contractility, ion channel function, and chamber‑specific pharmacological responses.

Watch the webinar: https://hubs.la/Q04rCVw50

Address

Cambridge
CB101XL

Telephone

+44(0)1223 751 051

Website

http://www.axolbio.com/

Alerts

Be the first to know and let us send you an email when Axol Bioscience Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Axol Bioscience Ltd.:

Want your business to be the top-listed Business in Cambridge?